Cancer Research and Treatment

Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes

Rongrong Fu, Rui Chang, Andong Peng, Changshun Feng, Weifan Zhu, Yi Chen, Xue Tian, Rui Wang, Hui Yan, Dianlong Jia, Jun Li

Pharmaceutical Development and Technology.2024; 29(1): 52. CrossRef

The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade

International Journal of Clinical Pharmacy.2024; 46(2): 368. CrossRef

Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis

Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Svenja Wöhrle, Larissa Fischer, Anna Kostina, Stephan Flemming, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian N. Parker, Andreas Boettcher, Christopher J

NLRP3 and cancer: Pathogenesis and therapeutic opportunities

Isak W. Tengesdal, Charles A. Dinarello, Carlo Marchetti

Pharmacology & Therapeutics.2023; 251: 108545. CrossRef

Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms

Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani, Mihnea-Alexandru Găman

World Journal of Hepatology.2023; 15(9): 1021. CrossRef

Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study

Feng-Ru Huang, Wen-Tong Fang, Zi-Ping Cheng, Ye Shen, Dun-Jian Wang, Yong-Qing Wang, Lu-Ning Sun

Archives of Toxicology.2022; 96(4): 1075. CrossRef

A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors

Ji Min Han, Jeong Yee, Soyeon Cho, Min Kyoung Kim, Jin Young Moon, Dasom Jung, Jung Sun Kim, Hye Sun Gwak

Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai

Juan Li, Bing Chen, Wen‐qi Xi, Wan Jia, Wei‐xia Zhang, Xiao‐lan Bian

The Journal of Clinical Pharmacology.2022; 62(9): 1160. CrossRef

A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity

Sitong Sun, Manshu Wang, Yu Yuan, Shuo Wang, Haoran Ding, Chenrui Liang, Xiaomeng Li, Simiao Fan, Yubo Li

Effects of High-Dose of Copper Amino Acid Complex on Laying Performance, Hematological and Biochemical Parameters, Organ Index, and Histopathology in Laying Hens

Qin Zhou, Jiaming Zhu, Bing Liu, Jialing Qiu, Xintao Lu, Brian Curtin, Fei Ji, Dongyou Yu

Biological Trace Element Research.2021; 199(8): 3045. CrossRef

Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile

Debasish Basak, Scott Arrighi, Yasenya Darwiche, Subrata Deb

Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study

Ji Min Han, Hye Won Han, Jeong Yee, Min Kyoung Kim, Jin Young Moon, Soyeon Cho, Dasom Jung, Yoon Sook Cho, Inyoung Seo, Jae Youn Kim, Hye Sun Gwak

European Journal of Clinical Pharmacology.2020; 76(8): 1183. CrossRef